FDA recommends against IO Biotech's BLA for melanoma vaccine

IO Biotech (IOBT) faced a significant setback as the FDA recommended against a Biologics License Application for its cancer vaccine Cylembio, following trial data that, despite showing improved progression-free survival in advanced melanoma, narrowly missed statistical significance. In response, the company plans a new registrational study, will engage EU regulators, and is implementing a 50% workforce reduction, while maintaining sufficient capital into Q1 2026. Morgan Stanley subsequently cut its price target to $4.00 from $6.00 but retained an Overweight rating, as IOBT prepares to present detailed trial data at ESMO in October 2025.

Analysis

IO Biotech (IOBT) has experienced a significant clinical and regulatory setback after the U.S. FDA recommended against the submission of a Biologics License Application for its primary asset, the cancer vaccine Cylembio. This decision stems from the IOB-013 trial in advanced melanoma, where the combination of Cylembio and pembrolizumab, despite improving median progression-free survival to 19.4 months versus 11.0 months for pembrolizumab alone, narrowly failed to achieve statistical significance. In response to this development, which carries a strongly negative sentiment score (-0.9 for IOBT), the company is initiating a major restructuring that includes a 50% workforce reduction to conserve capital. While management reports a cash runway into Q1 2026, InvestingPro data flags rapid cash burn as a key concern, a risk now amplified by the need to fund a new registrational study. Despite the setback, Morgan Stanley has maintained an Overweight rating while reducing its price target from $6.00 to $4.00, suggesting a view that the drug's demonstrated efficacy may still hold value. The next major catalyst will be the presentation of detailed trial data at the ESMO Congress in October 2025, which has been accepted as a late-breaking abstract, potentially offering a clearer path forward, particularly with European regulators.

Key Decisions for Investors

• Investors should recognize the significantly heightened risk profile and extended timeline for Cylembio's path to market in the U.S. following the negative FDA feedback.
• The upcoming ESMO Congress presentation in October 2025 is a critical catalyst; positive subgroup analysis or detailed data could support a regulatory path in the EU and partially de-risk the asset.
• Monitor the company's quarterly cash burn and capital position closely, as the announced restructuring may not be sufficient to fund a new pivotal trial without future dilutive financing.
• The dichotomy of Morgan Stanley's price target cut versus its maintained Overweight rating suggests a high-risk, high-reward scenario, justifying a speculative hold for investors with high risk tolerance but warranting caution for a broader investor base.